Loading...
Docoh
Log in Free sign up

Coeptis Therapeutics (COEP)

News

From Benzinga Pro
Bull Horn Holdings Corp. Combination Partner Coeptis Therapeutics Enters Into Exclusive Option Agreement With University Of Pittsburgh For Rights To CAR-T Technologies Designed To Target Multiple Cancer Indications, Including Hematologic And Solid Tumors
17 May 22
Biotech, General
Option agreement comprises three technologies and associated patent portfolios Announcement marks the third strategic agreement for Coeptis this quarter designed to bolster its portfolio and complement its innovative
Cancer-Focused Coeptis Therapeutics Turns To SPAC Deal To Uplist To NASDAQ
20 Apr 22
Biotech, News, Penny Stocks, Health Care, Financing, Offerings, IPOs, General
Statera Biopharma Reports Strategic Deal With Coeptis For Rights To Entolimod; Co. To Receive $6M Upfront Payment, Plus Sales-Based Milestone Payments
13 Apr 22
News, Contracts
Statera Biopharma (NASDAQ:STAB) (the “Company”), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced today that the Company has
Coeptis Therapeutics Intends To Acquire Statera's TLR5 Agonist Platform
13 Apr 22
Biotech, M&A, News, Penny Stocks, Health Care, Movers, Trading Ideas, General
Coeptis Therapeutics Announced Intent to Acquire TLR5 Agonist Platform, Including Clinical-Stage Asset Entolimod, from Statera Biopharma for $6M Plus Milestones
13 Apr 22
M&A, News, Penny Stocks, Asset Sales
Coeptis Therapeutics, Inc. (OTC PINK: COEP), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that the Company has entered into a strategic agreement with Statera Biopharma, Inc.

Press releases

From Benzinga Pro
Coeptis Therapeutics Enters into Exclusive Option Agreement with University of Pittsburgh for Rights to CAR-T Technologies Designed to Target Multiple Cancer Indications, Including Hematologic and Solid Tumors
17 May 22
Press Releases
Option agreement comprises three technologies and associated patent portfolios Announcement marks the third strategic agreement for Coeptis this quarter designed to bolster its portfolio and complement its innovative
Coeptis Therapeutics, Inc. and Bull Horn Holdings Corp. Announce Merger Agreement
19 Apr 22
Small Cap, Press Releases
Transaction expected to accelerate Coeptis' ability to progress its innovative cell therapy platforms for cancer David Mehalick of Coeptis to serve as Chief Executive Officer; Chris Calise of Bull Horn to join the
Statera Biopharma and Coeptis Therapeutics Announce Strategic Agreement for Rights to Entolimod
13 Apr 22
News, Financing, Press Releases
FORT COLLINS, Colo., April 13, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (NASDAQ:STAB) (the "Company"), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and
Coeptis Therapeutics Announces Intent to Acquire TLR5 Agonist Platform, Including Clinical-Stage Asset Entolimod, from Statera Biopharma
13 Apr 22
Small Cap, Press Releases
Entolimod is currently in clinical development as a potential treatment for acute radiation syndrome with additional preclinical programs advancing in neutropenia and anemia in cancer patients WEXFORD, Pa. , April 13,